REVIEW

Tall stature and gigantism in transition age: clinical and genetic aspects—a literature review and recommendations

V. Sada[1] · G. Puliani[2] · T. Feola[1,3] · R. Pirchio[4] · R. Pofi[1,5] · F. Sesti[1] · D. De Alcubierre[1] · M. E. Amodeo[6] · F. D'Aniello[6] ·
L. Vincenzi[1] · D. Gianfrilli[1] · A. M. Isidori[1,7] · A. B. Grossman[8,9] · E. Sbardella[1] on behalf of the TALENT group

Abstract

Purpose Tall stature is defined as height greater than the threshold of more than 2 standard deviations above the average population height for age, sex, and ethnicity. Many studies have described the main aspects of this condition during puberty, but an analysis of the characteristics that the physician should consider in the differential diagnosis of gigantism—tall stature secondary to a pituitary tumour—during the transition age (15–25 years) is still lacking.

Methods A comprehensive search of English-language original articles was conducted in the MEDLINE database (December 2021-March 2022). We selected all studies regarding epidemiology, genetic aspects, and the diagnosis of tall stature and gigantism during the transition age.

Results Generally, referrals for tall stature are not as frequent as expected because most cases are familial and are usually unreported by parents and patients to endocrinologists. For this reason, lacking such experience of tall stature, familiarity with many rarer overgrowth syndromes is essential. In the transition age, it is important but challenging to distinguish adolescents with high constitutional stature from those with gigantism. Pituitary gigantism is a rare disease in the transition age, but its systemic complications are very relevant for future health. Endocrine evaluation is crucial for identifying conditions that require hormonal treatment so that they can be treated early to improve the quality of life and prevent comorbidities of individual patient in this age range.

Conclusion The aim of our review is to provide a practical clinical approach to recognise adolescents, potentially affected by gigantism, as early as possible.

Keywords Gigantism · Tall stature · Transition age · GH

Introduction

Adult height shows distinct variability in the general population, following a normal Gaussian distribution dependent on age, sex, ethnicity, as well as many other factors. Human growth leading to final height is a composite and dynamic process, associated with phenotypic changes in stature, body proportions, and composition, reflecting the interplay of genetic, environmental, hormonal, nutritional, and socioeconomic factors [1].

Different endocrine factors regulate growth during each period of life, determining separate but closely integrated phases whereby many hormones influence transient growth and final height [2]. During the intrauterine phase, fetal growth is critically dependent on insulin and Insulin-like

Growth Factors (IGF), both maternal and placental, and nutritional status [3]. In the early years of life, nutrition is a pivotal factor, while in childhood, a crucial role is played by the GH/IGF1 axis. Nevertheless, thyroid hormones, adrenal androgens, glucocorticoids, sex steroids, ghrelin, leptin, and insulin are all known to participate in the growth process through their interactions with the GH/IGF1 axis. During puberty, the growth spurt depends on the interaction between the somatotroph and gonadal axes, which act synergistically towards the achievement of final stature [4, 5].

In a clinical context, deviations from a normal growth pattern can often represent the first evidence of a huge spectrum of diseases, encompassing both endocrine and non-endocrine disorders [6, 7]. While these deviations often manifest as growth inhibition or delay, excessive growth leading to tall stature may also reflect underlying pathological alterations.

Extended author information available on the last page of the article

Traditionally, 'tall stature' in children is defined as a height exceeding the 97.7th percentile or two standard deviations (SD) above the mean height for a population of the same age, sex, and ethnicity [8]. As a result, 2.3% of children fall into the category of tall stature and thus may be considered worthy of investigation [9]. Furthermore, children presenting with height within the normal range, but with a projected height surpassing 2SD above their mid-parental height, may also be evaluated. Although the percentage of children with tall stature is equal to that of children with 'short stature', referrals to paediatric endocrinologists for the assessment of tall stature appear to be far less frequent than those for short stature. This is probably due to a better societal acceptance of tall stature, along with the assumption that increased height in a child with tall parents is not alarming and is simply an acceptable familial trait. Indeed, clinical referrals become more likely whenever height exceeds > 2.5SD or > 3SD (extremely tall stature), respectively, 0.6% and 0.1% of the population [1]. Nevertheless, such patients require intensive investigation to establish any underlying pathological cause of increased growth, and to address potential problems of social adaptation [10].

'Familial tall stature', also known as constitutional tall stature, represents the most common cause and is considered as a variant of the normal pattern of childhood growth and development [11]. However, despite their rarity, many pathologic conditions also present with tall stature and may be associated with severe comorbidities [12]. Therefore, differentiating between healthy tall children and those with underlying diseases, while ruling out chromosomal, genetic, and endocrine disorders in the latter [13], poses a significant clinical challenge.

In the assessment of such children, measurement of current height, growth velocity, weight, head circumference, and body mass index (BMI) should be evaluated [14]. Additional diagnostic information should be gathered from birth data (weight, length, and head circumference), family history (height and pubertal timing of both parents), developmental history, and growth curve review, if available [15]. Assessment of body proportions is also critical: specifically, a head circumference > +2SD associated with tall stature could help clinicians to identify overgrowth syndromes, such as the Beckwith-Wiedemann, Sotos, Perlman, Simpson–Golabi–Behmel, Tatton–Brown–Rahman and Weaver syndromes [16, 17]. These overgrowth syndromes typically affect childhood from the prenatal to the postnatal phases, involving the development of the patients, in particular Beckwith-Wiedemann and Sotos syndromes that may be associated with hormone imbalance and increased susceptibility to malignancy [17]. The presence of cardiovascular abnormalities, skin anomalies, skeletal malformations, facial dysmorphisms, abnormalities of the genitalia, and

neurodevelopmental delay, may also suggest an underlying syndromic cause [18].

However, many of these genetic conditions exhibit overlapping phenotypes, thus complicating the differential diagnosis, particularly when dealing with patients in transition or adult age. Similar to children with short stature, 'constitutionally tall' individuals referred to the endocrinologist for an evaluation of the GH/IGF1 axis typically show no clear biochemical abnormalities [19]. Indeed, 'pituitary gigantism', excessive stature due to a primary hypothalamic-pituitary abnormality, is an extremely rare disease, with an estimated annual incidence of 8 per million, with only several hundred cases reported to date [20]. It may be a sporadic and isolated condition, and approximately half of the cases occur within the context of a concurrent hereditary syndrome or follow a familial inheritance pattern [3]. Excessive GH levels not only cause dramatic linear growth acceleration but can also lead to mild to moderate obesity, progressive macrocephaly, prognathism, and changes in glucose metabolism, including type 2 diabetes [21]. It is therefore vital, given the relevant number of comorbidities connected to a prolonged diagnostic delay, to identify such patients early and initiate appropriate therapy [22].

Although most children with short or tall stature do not have an underlying pathological condition, extreme deviations from average height, especially beyond + 3SDs, require further investigation. This review aims to provide a practical clinical approach to identify patients in the transition age (15–25 years) who may have underlying hypothalamic-pituitary defects, as opposed to idiopathic/constitutional tall stature. We conducted a comprehensive search of English-language original articles in the MEDLINE (PubMed) database between December 2021 and March 2022. The search used free text words in combination with Medical Subject Heading (MeSH) terms. The keywords applied for the search included the "*Gigantism*" term as a keyword and "*human*" as a filter.

Clinical approach

Auxology with a focus on the transition age

As noted above, tall stature is generally defined as height measurements exceeding the threshold > +2SDs above the average population height for age, sex, and ethnicity, corresponding to the 97th percentile of each growth chart [14]. Ideally, each country should have its own growth chart. In this regard, Natale et al. performed a systematic review comparing data from the World Health Organization (WHO) *Multicenter Growth Reference Study* with data from studies performed in 55 countries or ethnic groups, including over 11 million children from economically advantaged

backgrounds. They highlighted differences in average stature between groups, identifying a 'tall group' (with height means three or more ages above the + 0.5SD mark compared to the general population) in Europeans and Pacific Islanders, thus suggesting that the use of a single international standard for anthropometric measurements may not be entirely justified. As a result, they created a large-scale comparison of growth in healthy children around the world [23]. In case a country-specific growth chart is unavailable, patients should nevertheless be referred to WHO growth charts for children and adolescents, spanning from birth to 19 years of age. According to the WHO, a height at + 2SD in adults corresponds to 191.1 cm in men and 176.2 cm in women (WHO, 2006) [24].

Tall stature is also defined by a height value over > + 2SDs above the Target Height (TH) SD score. TH can be derived by calculating the mean height of both parents and then adding or subtracting 6.5 cm for boys and girls, respectively. The definition of the target range, considering the overall secular trend of increasing average height, typically falls within 1.6–2 SD of the TH-SDs. This definition helps clinicians to identify cases of familial idiopathic tall stature, especially in the absence of dysmorphism or known parental disease [6].

Puberty

When interpreting tall stature, several factors should be taken into account, including age, sex, genetics, nutrition, and pubertal development [25, 26]; notably, the latter is one of the most relevant elements, especially during the transition age. A correct evaluation of sexual development should include pubertal assessment according to Tanner's staging system, evaluating genital and breast changes, as well as the development of pubic and axillary hair in both girls and boys, while for the measurements of testicular volume in boys, the Prader orchidometer is useful [27]. Reassuring indicators suggesting a diagnosis of non-pathological tall stature include: tall stature accompanied by normal pubertal progression; height within the TH associated with regular Height Velocity (HV), and bone age corresponding to chronological age [28]. A recent study showed that girls with tall stature may enter puberty earlier but remain in the normal range for pubertal onset, compared with girls with normal or short stature, probably influenced by IGF1 levels [29]. Conversely, when the auxological parameters do not develop harmonically – especially in the case of altered pubertal progression—various pathological scenarios should be considered.

Focusing on the transition age, when evaluating a child for tall stature, one condition to be excluded is precocious puberty, when the child can initially present with temporarily increased growth due to the anabolic effect of sex steroids; however, it should be noted that this condition ultimately leads to a *short* final height if left untreated, due to the gonadal steroid-induced premature closure of the epiphyses [30–32]. Another aspect that should be considered is overweight/obesity, which has been widely described as a risk factor for central precocious puberty [33], especially in girls. For this reason, when evaluating a tall child with overweight/obesity, careful physical examination of sexual development should be carried out to rule out any signs of pubertal onset. Other forms of precocious puberty associated with tall stature may be part of syndromic conditions, such as the McCune–Albright syndrome (MAS) [34] or Neurofibromatosis Type 1 (NF1) [35]. On the contrary, extremely delayed puberty in tall adolescents could be indicative of gonadal failure, as seen in Klinefelter Syndrome [36].

Pituitary gigantism

Since gigantism is caused by GH/IGF1 excess which occurs before the fusion of the epiphyseal growth plates, it is a condition exclusively observed in children and adolescents, either before or during puberty. The transition age is a critical phase, since elevated levels of serum GH and IGF1 can cause rapid, excessive linear growth, potentially resulting in extremely tall adult stature if left unchecked. Mild to moderate obesity commonly accompanies tall stature in these patients; specifically, in children with GH excess, the abnormal height growth typically precedes or occurs simultaneously with rapid weight gain [37], whereas children with exogenous obesity typically exhibit increases in their weight percentile before any changes in height are noted [38]. In contrast, in adulthood, because of complete epiphyseal fusion, GH excess has no effect on stature and is responsible for the clinical features of acromegaly [37, 39].

Dramatic linear growth acceleration usually prompts initial medical investigation in children. The mean onset of rapid growth in children with pituitary gigantism has been reported to occur at the age of 13 years, and even earlier in girls [39]. Among different forms of gigantism, X-linked acro-gigantism (XLAG) is associated with the earliest onset of rapid growth, with a median age of onset of 1.5 years; these patients typically reach their final height at 23.5 years, deviating from the TH by about 10.9 cm (6.52%). Conversely, individuals with *AIP* mutations and those with genetically negative forms of gigantism typically show a later onset of growth acceleration (13–14 years), reaching their final height at 19–20 years with a more significant difference from TH, approximately 19–21 cm (10.9–12.7%) [39].

Clinical presentation of gigantism during the transition age

Gigantism and acromegaly represent two clinical manifestations of the same pathological entity—namely a GH-secreting pituitary adenoma, also known as a pituitary neuroendocrine tumour (PitNET). The clinical phenotype largely depends on the timing of disease onset in relation to skeletal maturation. GH excess determines a continuum of clinical manifestations that can occur both before and after the fusion of the epiphyseal growth plates, with frequent overlap [40]: many of these patients will have features of acromegaly in conjunction with gigantism, hence the term 'acro-gigantism'.

Apart from scattered case reports, only two studies have reported the clinical presentation of patients with pituitary gigantism diagnosed during the transition age [39, 41, 42]: a single-centre study by Colao et al. conducted on 13 patients diagnosed between 15 and 20 years, and a multicentre study by Rostomyan et al. investigating more than 200 patients with a wider age at diagnosis (median 21 years, interquartile range 15.5–27) [39]. Tall stature is usually the first clinical sign that leads to medical attention, thus initiating the diagnostic process for gigantism. In particular, patients with pituitary gigantism show a peculiar growth pattern, in which the young patient, who was not initially born large for gestational age, progressively crosses higher percentiles during childhood, eventually reaching an adult height above 2SD and surpassing their genetic TH [9]. The onset of growth acceleration has been demonstrated to occur significantly earlier in females than in males (median age of onset: 11 *vs* 13 years). Additionally, a shorter diagnostic delay from symptoms onset to diagnosis has been found in females, resulting in a significantly lower age at the time of gigantism in females than in males (median age at diagnosis: 15.8 *vs* 21.5 years) [39]. Therefore, males are more likely to be diagnosed during the transition age. Of note, not all patients reportedly had attained their final height at the time of diagnosis, particularly male patients [39]. While tall stature is generally the primary presentation-presenting feature, the pathological effects of the prolonged exposition to supraphysiological levels of GH and IGF1 are systemic. Patients with gigantism may also show acral enlargement and facial changes, which represent the second most frequent clinical sign (37%). The median shoe size reported at diagnosis was 48 (EU) in males and 42 in females. Acromegalic features were already present at diagnosis in patients with gigantism regardless of sex and age, although facial changes were less commonly observed in patients aged < 19 years [39]; similarly, signs and symptoms typical of acromegaly such as joint disorders and sweating were rarely encountered in younger patients.

Since most patients with gigantism often harbour macro- and giant pituitary tumours, signs and symptoms of compression are frequently observed at diagnosis, with headache and visual field defects being reported in 23% and 12% of patients, respectively. In addition to visual field impairment, lachrymation, transitory eyelid palsy, or ptosis have also been reported [41]. Furthermore, around a quarter of patients exhibited at least one pituitary deficit; hypogonadism was diagnosed in 40% of patients at diagnosis [39]. In line with these findings, one study reported the presence of amenorrhoea, both primary and secondary, in all female patients with gigantism [41]. Prolactin co-secretion has been reported in more than 30% of cases, particularly in patients with invasive and extrasellar pituitary tumours, with galactorrhoea reportedly being slightly more frequent in females [39]. Moreover, typical GH excess complications such as sleep apnoea, carpal tunnel syndrome, hypertension, and glucose metabolism disorders were already present at diagnosis, particularly in patients aged > 20 years [39].

Alterations in glucose and lipid metabolism may be seen in patients with gigantism; insulin-resistance has been mainly found at diagnosis [41], whereas glucose intolerance and overt diabetes mellitus have been reported less frequently at diagnosis, particularly in patients < 19 years [39].

Concerning cardiovascular disease, cardiac impairment was detected at diagnosis in 36.5% of cases, primarily involving left ventricular hypertrophy (21%) and diastolic dysfunction (10%) [39]. In one study comparing the echocardiographic parameters of six males diagnosed with pituitary gigantism during adulthood with those of six age- and sex-matched acromegalic patients and ten healthy controls, both groups of patients displayed significantly higher left ventricular mass index, interventricular septum diastolic thickness, and posterior wall thickness compared to controls. Although patients with gigantism exhibited a significantly longer disease duration, no relevant differences in cardiac structure and performance were noted in these patients when compared to acromegalic patients. However, individuals with cardiac abnormalities in the gigantism group exhibited higher IGF1 levels than those with a normal cardiac structure. For this reason, the authors of this paper suggest performing echocardiography regardless of disease duration to detect cardiac impairment early [40]. Apart from one case [40], no alterations in blood pressure or heart rate have been found in patients with gigantism [41].

Thus, in patients diagnosed during the transition age, it is necessary to not only focus on tall stature and external changes but also investigate potential systemic complications.

Clinical approach

The clinical approach to tall children during transition age should include, wherever possible:

– *Birth data (weight, length, and head circumference);*
– *Familial auxological parameters: height/weight for parents and first-degree relatives, pubertal timing of parents (age of menarche of the mother, age of the pubertal growth spurt of the father);*
– *Personal medical history: hypo/hyper-glycaemia, metabolic disorders, over-feeding, cardiac defects, ocular defects, anosmia, ligamentous laxity, joint dislocation, obesity, and neurodevelopmental disorders;*
– *Assessment of standing height, sitting height, arm span, weight, BMI and head circumference, as compared to country-specific growth charts;*
– *Assessment of pubertal status according to Prader's scale, Marshall and Tanner staging;*
– *Assessment of HV: calculated at least every 6 months, expressed in cm per year (cm/yr) with particular attention to peak-height-velocity indicating a pubertal spurt [43];*
– *Clinical evaluation: cardiac murmurs, anomalies of the skin, skeletal examination (pectus excavatum, scoliosis), and facial dysmorphism;*

The initial approach to a tall child in the transition age should also incorporate the determination of bone age according to a standardised model (for example, the Greulich and Pyle atlas or the Tanner-Whitehouse atlas version 2 or 3 [44]) to distinguish between a physiological constitutional growth delay or familial tall stature—characterised by a normal/delayed bone age—and pathological precocious puberty, characterised by advanced bone age. Especially during the peri-pubertal transition age, it is crucial that growth assessments be performed regularly; when determining the normality of a child's growth pattern, serial height measurements of HV calculations are more useful than a single height-for-age percentile. A child that grows regularly on a high percentile (even above the 97th percentile), without significant comorbidities, and especially with a family history of tall stature, should generally be considered a normal variant. Conversely, rapid acceleration of growth, regardless of the percentile, should be investigated further to rule out pathological causes [45]. Transient tall stature can also be observed in patients with true precocious and pseudo-precocious puberty.

The most prevalent cause of tall stature is familial tall stature, characterised by tall parents, normal growth velocity, normal findings on physical examination, and correspondence between bone age and the chronologic age. Stature generally remains in the target genetic range [8]. Sometimes this condition is characterised by an acceleration in growth velocity in early childhood, between 2 and 4 years of age. Growth progression remains slightly above the normal curve, following the same centiles until puberty. Rarely, children may also exhibit advanced bone age and early pubertal development within the normal range. Pagani et al. suggested the possibility of GH hypersecretion in children with familial tall stature, as supported by the presence of age- and sex-adjusted IGF1 levels in the upper range of normal, or hypersensitivity to GH [46].

Another physiological cause of tall stature is, paradoxically, constitutional delay of growth and development (CDGD). This may occur not only in children from short or normal-statured families but also in children of tall-stature families. A study published in 2005 analysed a cohort of adolescents aged 12–16 years and demonstrated that the final height of CDGD children exceeded the mean TH by more than 4 cm, reaching a mean value of + 1.9 and 2.1SD for boys and girls, respectively—consistent with final tall stature—in 42% of cases [47].

Certain genetic conditions, such as Marfan Syndrome, may be characterised by tall stature, with a rapid increase in growth velocity occurring just before or in the early stages of the transition age. For this reason, Disease-specific Growth Charts of Marfan Syndrome patients have been developed in some countries. The syndrome, caused by mutations in the fibrillin-1 (*FBN1,* chromosome 15q) gene and dysregulation of transforming growth factor β (TGFβ), affects the skeletal system, resulting in tall stature, abnormally long and slender limbs, fingers, and toes, chest wall abnormality, and scoliosis. The arm span is greater than their height, with an arm span-to-height ratio greater than 1, while the upper/lower segment ratio is diminished [48]. A Korean study showed that the 50th percentile of height in patients with Marfan Syndrome exceeds the normative 97th percentile for both genders [49]. A French study comparing more than 250 Marfan patients to a control population demonstrated that Marfan children's overgrowth decreases with age, especially during the transition phase, at about 17 years of age [50]. Another important aspect deals with the specific mutation of Marfan Syndrome since patients carrying *TGFBR2* mutations have lower mean height than patients harbouring *FBN1* mutations [51].

Klinefelter syndrome also exhibits its peculiar growth pattern, with normal auxological parameters during infancy, followed by a rapid growth tall stature between 5 and 8 years of age, and further growth in the pubertal period [52]. Thus, disease-specific growth charts can be useful for monitoring growth patterns, planning the timing of growth-reductive therapy if necessary, and predicting adult height.

In conclusion, for correct identification of tall stature, it is necessary to report the height value on country-specific or disease-specific growth charts. A systematic clinical approach,

Table 1 Main differential diagnoses for tall stature

Differential diagnosis	Bone age	Centile crossing	HVR	Puberty (N, P or D)	Anatomical features
Transition Age					
Familial Tall Stature	↑/→	< 2 SD	→	N	Normal appearance
FIPA	NA	> 2 SD	NA	N	Tall stature
MAS	↑	NA	↑	P	Café-au-lait spots, skeletal lesions (fibrous osteodysplasia), craniofacial dysplasia (optic and auditory nerve impairment)
Marfan syndrome	NA	> 97th percentile	↑	N	Abnormally long and slender limbs, fingers, toes, chest wall, and scoliosis
Klinefelter syndrome	→	> 2 SD	↑/→*	N	Small, firm testes; gynecomastia; high-pitched voice; learning disability
Hyperthyroidism	↑	< 2 SD	↑	N	Goiter, tachycardia, hypertension, diarrhea, exophthalmos
Obesity	↑	> 2 SD	↑	P	BMI > 95th percentile
Childhood					
Beckwith-Wiedemann syndrome	↑	≥ 2 SD	↓*	NA	Macroglossia, abdominal wall defects, congenital heart disease,
Sotos syndrome	↑	> 2 SD	↑	P#	Macrodolichocephaly, facial alteration
Weaver syndrome	↑	> 98th percentile	NA	NA	Abnormal facial alteration
Simpson–Golabi–Behmel syndrome	↑	> 97th percentile	NA	NA	Macrocephaly, ocular hypertelorism (wide-spaced eyes) with broad upturned nose, macroglossia, and macrostomia (large mouth), supernumerary nipples, pectus excavatum, and hypotonia
Perlman syndrome	NA°	75th–97th percentile	NA°	NA°	Macrosomia, macrocephaly, round facies, hypotonia, visceromegaly, cryptorchidism and inguinal hernia
Tatton–Brown–Rahman syndrome	NA	N/> 2 SD	NA	P	Macrocephaly noticed at birth, joint hyperlaxity, scoliosis, hypotonia, and seizures

HVR Height Velocity Rate; *SD* Standard Deviation; *N* normal onset, *P* precocious, *D* Delayed, *NA* Not Available; *FIPA* Familial Isolated Pituitary Adenomas; *NF1* Neurofibromatosis type 1; *MAS* McCune-Albright Syndrome; *BMI* Body Mass Index

#especially in female patients

*after 8 years old, before HVR is increased

°due to high mortality rate in the neonatal period

along with the periodic monitoring of auxological parameters and HV, is essential for distinguishing between physiological and pathological causes of tall stature.

Table 1 summarises the main differential diagnoses for tall stature.

Genetics

Genetic background of acro-gigantism

Although the most frequent pathological cause of GH excess is represented by apparently sporadic PitNETs, around half of all patients with gigantism have a genetic background. In adolescence and young adulthood, the most common genetic causes of acro-gigantism are *familial isolated pituitary adenomas* (FIPA), in which pituitary tumours occur in two or more family members without other syndromic

manifestations, and multiple neuroendocrine neoplasia type 1 (MEN1), in which pituitary tumours are associated (often not synchronously) with primary hyperparathyroidism (pHPT), or other NETs, generally of gastro-enteropancreatic origin (GEP-NETs) [53]. Exceptionally, acro-gigantism can also manifest in adolescent patients affected by multiple neuroendocrine neoplasia type 4 (MEN4) or other rare genetic syndromes such as the Carney complex or MAS. However, the putative genetic cause of acro-gigantism remains unclear in approximately 50% of patients and often associated with more aggressive tumour behaviour [39]. Figure 1 represents the main genetic causes of acro-gigantism in the transition age.

Familial isolated pituitary adenoma (FIPA)

In the transition age, the most frequent cause of acro-gigantism in patients with FIPA is the presence of loss-of-function

Fig. 1 Representation of possible genetic causes of acro-gigantism during the transition age

mutations in the gene coding for the aryl hydrocarbon receptor-interacting protein (AIP) [54], which account for 29% of cases of pituitary gigantism, as reported in the largest multicentre European study to date (208 patients with gigantism) [39]. *AIP* is a tumour suppressor gene, located on chromosome 11q13.3, encoding for a co-chaperone protein involved in the signalling of cyclic adenosine monophosphate through the binding with phosphodiesterase subtype 4A5, although it has been associated with many additional functions. Mutations of *AIP* are inherited in an autosomal dominant manner but with an incomplete, generally low (around 30%) penetrance, and high phenotypic variability [55, 56]. These genetic characteristics may explain why germline *AIP* mutations can also be found in patients with apparent sporadically diagnosed GH-secreting tumours, even in the absence of family history, most likely reflecting the low penetrance rather than the onset of de novo mutations [57]. Genetic diagnosis is based on gene sequencing and, if negative, on multiple ligation probe amplification (MLPA) [53].

Patients with a germline *AIP* mutation typically present large, invasive tumours (macroadenomas 90%, and giant 10% [39]) often with an extrasellar extension, a higher likelihood of pituitary apoplexy, and frequently aggressive clinical behaviour [58]. The typical age of onset is in the second decade of life, with symptoms manifesting before 18–19 years in most cases (65–71.4%) [39, 58]. Gigantism is observed in about a third of cases [55]; typical features of acromegaly are also common despite the young age of onset, depending on GH/IGF1 levels and the diagnostic delay [39]. Indeed, rapid growth acceleration typically starts at a median age of 13 years (9–15 years), with a delay from first symptoms to diagnosis of 3 years (1–6 years) [39], which contributes to a longer period of linear growth that may also be exacerbated by concomitant hypogonadism [39]. A male predominance has been observed in most of the published series [39, 59–62], unlike other causes of gigantism that are more common in females (X-LAG, MEN1, unknown genetic causes). Of note, early diagnosis in *AIP* mutation carriers leads to the detection of smaller lesions with less suprasellar extension or cavernous sinus invasion, which are therefore less difficult to manage compared to clinically symptomatic cases [58]. Similarly, earlier diagnosis, with associated accelerated disease control, may also help to reduce the final height in such patients [39], further

demonstrating the benefits of genetic and clinical screening for pituitary diseases in carrier patients via genetic counselling and surveillance. When the *AIP* mutation is found in the proband, genetic counselling should be proposed to all first-degree relatives, as the disease may already manifest as early as the age of 4 years [63]. Regular clinical follow-up should be performed in *AIP* mutations carriers throughout the transition age, with an annual physical examination and hormone assessment (GH, IGF1, and prolactin) and baseline MRI, followed by 5-yearly scans, until the age of 20; in case no abnormalities are detected, the clinical follow-up in the second decade of life can be less frequent [58].

Following the identification of a loss-of-function variant (p. Arg703Gln) in the PAM (peptidylglycine α-amidating mono-oxygenase) gene in a three-member FIPA acro-gigantism family, a recent study by Trivellin et al. examined 299 individuals with sporadic pituitary adenomas and 17 FIPAs kindreds, identifying rare PAM variants in two subjects with sporadic acromegaly and gigantism (p.Gly552Arg and p.Phe759Ser, respectively), suggesting that PAM could be a candidate gene associated with their disease. These patients varied from micro- to macroadenomas. Further studies, including more subjects affected by the most common pituitary hypersecretion such as hyperprolactinemia, are needed to better explain the possible role of PAM in pituitary tumorigenesis [64].

Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)

MEN1 is an autosomal dominant disorder predisposing to the development of neoplasms, mostly in neuroendocrine tissues [65]. It is caused by inactivating mutations of the *MEN1* gene, located on 11q13, which encodes for menin, a protein involved in cell proliferation, histone methylation, and gene transcription [66, 67]. The prevalence of MEN1 is currently estimated to be between 1/30,000 and 1/500,000 [68, 69]. From a clinical standpoint, the syndrome can occur in a sporadic (10% of cases) or a familial setting (90% of cases), usually within the fourth decade of life [70]. MEN1 is characterised by high penetrance, with 95% of mutation carriers showing biochemical evidence of disease and 80% developing clinical signs by the age of 50 years [71]. Pit-NETs are the first MEN1-associated lesion in 25% of sporadic and 10% of familial cases [72], with a subtype distribution reflecting the one observed in the general population. Moreover, MEN1-PitNETs have been described as more frequent in female patients, as well as being larger, more invasive lesions, less controllable by standard treatments [73], although this has been disputed.

Despite the high penetrance of MEN1, data regarding paediatric and adolescent patients are scarce, as only a few studies have retrospectively reported data regarding clinical outcomes and natural history in young MEN1 patients [25, 74–77]. In this regard, a large study by Goudet et al. [75] retrospectively analysed 122 MEN1 patients under 21 years, describing their clinical symptoms, and biological and/or imaging abnormalities. The presence of a pituitary lesion was seen in 34% of these young patients, mainly in the 16–20 years age group. Interestingly, no PitNETs occurred before the age of 10 years; moreover, in the entire cohort, only 2% of pituitary lesions turned out to be GH-secreting. Similarly, in several retrospective cohorts focusing on young MEN1 patients, no somatotrophinomas were reported, confirming these to be extremely rare in adolescent MEN1 patients and even rarer in the paediatric age [25, 74–77]. As a result, pituitary gigantism is an uncommon finding in young MEN1 patients; the largest series to date, which analysed 208 patients with gigantism across multiple European centres, reported identifiable MEN1 mutations in just 1% of patients [39].

It should be noted that, in MEN1 patients, GH excess and subsequent acromegaly may instead derive from ectopic growth hormone releasing-hormone (GHRH) secretion by neuroendocrine pancreatic tumours [78]. Interestingly, MEN1 has been reported to account for up to 76% of GHRH-secreting NETs [79]. In this context, diagnosis usually occurs during the third decade of life [78] with a slight female predominance (60% of cases) [79].

The presentation of gigantism due to ectopic GHRH secretion, generally from a well-differentiated NET [78, 80], is characterised by accelerated growth with abnormal height without mass-related symptoms (headache and/or visual impairment); notably, GH excess reverts after surgical resection of the NET [80].

In 2006, germline mutations in the cyclin-dependent kinase inhibitor 1b gene (*CDKN1B*), encoding for the known oncosuppressor p27, were detected in patients exhibiting MEN1-like features with no apparent *MEN1* mutation [81]. This finding led to the identification of MEN4, an extremely rare autosomal dominant condition, which has only been described in a handful of case reports worldwide to date [82]. Patients with MEN4 present with a MEN1-like phenotype and are therefore prone to the development of NETs, including PitNETs [83] in up to one-third of total cases [82]. Specifically, MEN4-related somatotrophinomas have been reported to occur in all age groups [81, 84, 85]; however, due to the rarity of the disease, data regarding paediatric and/or transition-age patients are still lacking, with a single case reported to date. Sambugaro et al. [85] reported on a patient with early onset, aggressive acromegaly in a 30-year-old woman. At age 5, the patient had undergone clinical investigations due to excessive growth velocity, leading to the diagnosis of GH hypersecretion due to a pituitary macroadenoma. Despite multimodal treatment, biochemical control was not achieved, requiring long-term medical therapy.

Genetic investigations did not detect germline *AIP* or *MEN1* mutations, leading to the identification of a deletion in the *CDKN1B* 5′-UTR region and the diagnosis of MEN4 [85].

Rare genetic syndromes

Carney complex syndrome (CCS) is a rare genetic syndrome including multiple endocrine and non-endocrine neoplasms, whose diagnosis is based on the presence of two or more of the following manifestations: skin pigmentation, cardiac myxomas, primary pigmented nodular adrenocortical lesions, large cell calcifying Sertoli cell tumours, ductal adenomas, pustular melanomas, blue naevi, osteochondral myxomas, thyroid tumours, and acromegaly [86]. In 30% of cases, it is caused by de novo mutations in the suppressor gene for PRKAR1A (*CNC1*) at 17q24.2, encoding for the regulatory subunit type 1α of the protein kinase A [87]. CCS is generally diagnosed over 20 years of age; in this context, acromegaly is observed in 10–18% of cases, with a female predominance [86]. In a French multicentre prospective study including 70 CCS patients (50 females, mean age 35.4 ± 16.7 years, 81% carrying a PRKAR1A gene mutation), annual systematic screening highlighted that acromegaly had a prevalence of 18%, although clinical signs of GH excess were generally mild or absent. A higher percentage of patients (30%) presented with non-diagnostic biochemical abnormalities of the somatotroph axis [87]; interestingly, "subclinical acromegaly" might also be associated with the development of cardiac myxomas [87]. Other genetic alterations associated with CCS include abnormalities in *CNC2*, located at 2p16, and activating mutations for PRKAR1B, the catalytic subunit beta (Cβ) of PKA [86, 88]. The latter was found in a young woman with CCS who presented at 19 years old with acromegaly, pigmented spots, and a myxoma [88].

MAS is another rare cause of acro-gigantism during the transition age. This syndrome, caused by somatic gain-of-function mutations of the *GNAS* gene encoding the α-subunit of the Gs signalling protein, is characterised by the presence of skeletal lesions (fibrous osteodysplasia), café-au-lait spots, and hyperfunctioning endocrinopathies such as precocious puberty [89]. Acro-gigantism in MAS typically affects male patients, with a variable age of onset – ranging from childhood to young adulthood—and frequent prolactin co-secretion. GH excess may worsen the skeletal deformities associated with this syndrome, especially craniofacial dysplasia, resulting in optic and auditory nerve impairment [86], and complicates pituitary surgery.

Over the last decade, new genetic causes of multiple endocrine tumours have been identified. Co-existing phaeochromocytomas and pituitary adenomas (3Pas) are usually associated with SDHx mutations, in which pituitary tumours are larger and more aggressive, generally occurring in adulthood, although several cases have been described in young patients. Specifically, 9 cases of GH-secreting tumours (one co-secreting prolactin), all macro-tumours, have been reported in patients younger than 30 years [90]. Recently, the Liege group described three cases of phaeochromocytomas associated with pituitary adenomas in patients with germline heterozygous *MAX* exon deletions. Two of these cases showed a GH-secreting tumour occurring at a relatively young age (a 26-year-old female and a 16-year-old male) [91].

Lastly, GH excess during the transition age and young adulthood may be associated with NF1 syndrome. In a recently published retrospective case series, two cases of young patients exhibiting clinical and biochemical acromegaly, a 14-year-old Hispanic male with a macroadenoma and a 29-year-old Caucasian female with a pituitary hyperplasia, were reported [92].

In conclusion, during the transition age the presence of *AIP* mutations should be suspected in patients with acro-gigantism, particularly in males, with an onset in adolescence (< 18y) or young adulthood (20-30y), independent of a positive family history. Conversely, gigantism is an extremely rare occurrence in the context of MEN1 and MEN4, and then with a female preponderance; rarely, acro-gigantism may be diagnosed in adolescence and young adulthood in the context of other genetic disorders, such as CCS, MAS, 3Pas, MAX-associated tumours, NF1, and the recently identified PAM variants.

Early diagnosis and treatment have been demonstrated to halt clinical progression and prevent further growth, and therefore genetic counselling in this age group is mandatory.

Other differential diagnoses

Hyperthyroidism

Hyperthyroidism is uncommon during childhood and adolescence, with an annual incidence in childhood ranging from 1 to 6.5 per 10,000 individuals in different studies [93–95]. The most frequent cause is Graves' disease; other differential diagnosis includes MAS, activating mutations of the TSH receptor gene, toxic nodules, and exogenous thyroid hormone administration [96]. Linear growth can also be affected, resulting in increased HV rate and advanced bone age [97]. Interestingly, the final height is generally not compromised, with only some patients achieving a final height exceeding the estimated target [97]. However, more frequently, children are below 2SD for height [98]. In addition, the appropriate treatment strategy determines the adult final height within the normal range [9]. Thyroid hormones have been shown to increase the expression and release of GH from the pituitary in animal studies [99]. Conversely,

patients affected by hypothyroidism show lower levels of IGF1 [100, 101], and treatment with levothyroxine has been found to increase serum levels of IGFBP1 [102]. Thyroid hormones also modulate the biological effects of GH and IGF1 on target tissues [103]. Therefore, it is essential to assess thyroid function in all patients presenting with tall stature.

Obesity

Many studies have demonstrated that obesity in children is associated with an increase in growth velocity and final stature. In fact, children affected by obesity have been reported to be 4–5 cm taller than normal-weight controls, with an advanced bone age and early puberty [9, 104]. In this context, one study investigating potential differences in stature and skeletal maturity, in 521 subjects from birth to 18 years according to BMI, demonstrated that obesity was associated with increased final height, especially for girls aged 10–12 years, and for boys aged 11–13 years. Moreover, in overweight/obese adults, skeletal maturity is advanced throughout childhood [105]. The impact of obesity on final height seems to vary depending on the individual's age of onset and sex: obesity at approximately 11 years of age was associated with the most increase in height (5.7 cm in females and 4.5 cm in males) [106].

Obesity causes a decrease in GH secretion and a blunted response of GH to various stimuli [107], probably due to increased somatostatin levels [108]. On the contrary, IGF1 levels are usually normal or high, presumably because of the effects of insulin. One study demonstrated that obesity could increase IGF1 levels in pre-pubertal children, who have a greater response to GH compared to children with tall stature [109]. Concurrently, circulating levels of ghrelin are lower in obese children and adolescents compared to their normal-weight peers, with circulating levels correlating with the degree of insulin resistance [110]. Thus, obesity can result in an increase in growth velocity, especially if the condition appears in the late pre-pubertal or early pubertal phase, and should therefore be considered in the differential diagnosis of tall stature.

Doping

The term 'doping' refers to the use of performance-enhancing substances in non-pharmacologic doses to improve sports performance [111]. Abuse of GH is widespread and has been reported in 27% of young male weightlifters [112], even extending beyond professional contexts [113]. During childhood and adolescence, abuse of GH causes further damage, since the achievement of normal pubertal growth and adult body composition is dependent on the GH/IGF1 and hypothalamo-pituitary–gonadal axes, but data are scarce [114, 115]. During adolescence and the transition age, detecting GH abuse can be challenging, since GH and IGF1 levels naturally rise in this period, but the *GH-2000* method, which also assesses pro-collagen type III N-terminal peptide levels, also seems to be a reliable detection tool in this age group. [116].

Biochemical diagnosis

GH and IGF1 assessment

The differential diagnosis of tall stature is complex given the heterogenous presentation of the rare conditions that cause pathological increases in height [39, 117, 118]. There are currently no evidence-based recommendations to determine which patients should be evaluated for pathological causes of tall stature, or to inform the best strategy for investigation. A thorough clinical evaluation is mandatory before going through the biochemical assessment [119].

Generally, serum IGF1 is recommended as the best screening test due to its excellent linear dose–response correlation with 24 h mean GH secretion [120]. Nevertheless, no published studies have ever defined a dedicated IGF1 reference range to guide the difficult differential diagnosis between tall stature and gigantism. It is, therefore, crucial to use age-referenced ranges, as potential misdiagnoses may arise when evaluating normal adolescents due to their significantly increased IGF1 levels during puberty with respect to adulthood [121, 122]. A study by Creo et al., focusing on patients with pituitary gigantism, showed that the subjects' IGF1 levels did not significantly differ much from the normal laboratory range, thus demonstrating that relying solely on IGF1 values may not suffice for diagnosing gigantism, highlighting the need for an integrated diagnostic approach including clinical features and growth patterns [123]. Furthermore, recent evidence has highlighted a potential role of the IGF2 protein, traditionally known for its involvement in normal fetal development due to its secretion via the placenta during pregnancy. In the post-natal period, IGF2 secretion mostly derives from hepatocytes independent of GH secretion. Interestingly, IGF2 overexpression has been observed in two rare conditions characterized by fetal overgrowth, namely Beckwith-Wiedemann and Perlman syndrome [17, 124]; however, its potential role in acro-gigantism still requires elucidation.

Random/morning serum GH levels interpretation is also challenging, being affected by its pulsatility, lack of uniform assay standardisation, poor reproducibility between laboratories, and, importantly, the lack of reliable reference values for sensitive immunometric assays [125]. Some authors have demonstrated basal GH levels to correlate with GH day-curves and nadir GH levels after an oral glucose tolerance

test (OGTT) [126, 127], but these procedures are often neglected, being both time-consuming and cumbersome.

Nevertheless, pituitary adenomas in patients with gigantism are often highly secretory, leading to significantly elevated GH and IGF1 levels [128]. An OGTT test for GH levels associated with cranial MRI in children with height above 2SD and IGF1 circulating levels approaching the upper limit of normal are crucial steps in confirming or ruling out the diagnosis of gigantism [14].

Previous, and older, expert consensus suggested a failure to suppress serum GH levels to less than 5 µg/L after a 1.75 mg/kg oral glucose challenge (maximum, 75 g) as the gold standard for diagnosing gigantism [128]. However, there is no mention of a different diagnostic approach between acromegaly and gigantism in the latest *Endocrine Society* guidelines [129], therefore suggesting a serum GH cut-off of < 1 µg/L (or < 0.4 µg/L in ultra-sensitive new available assays [130]) within 2 h after a 75 g of oral glucose load to be regarded as confirmatory for gigantism [129]. Prolactin may be raised with pituitary tumours, while thyroid hormones, oestrogens, and androgens need assessment [3].

Notably, androgens mediate the growth spurt, partly through conversion to oestrogen but also through direct effects in the growth plate [2]. Children with precocious puberty or virilising disorders generally exhibit increased growth velocity and height SDs compared to their peers, which leads to advanced bone age and short stature in adulthood if not recognised, prevented, and treated [118, 131]. Conversely, conditions characterised by decreased levels or reduced sensitivity to sex hormones (hypogonadism, aromatase deficiency, and oestrogen resistance) can lead to prolonged growth due to delayed growth plate fusion. Although the growth rate in these cases is slow, these children keep growing into adulthood, developing tall stature (often with eunuchoid proportions) only later in life [2]. It is important to underline that treatment for pituitary gigantism (i.e., surgery and/or radiotherapy [132]) might lead to secondary hypogonadism [133], which may further increase the adult height if not adequately treated [39].

In cases of precocious puberty, further evaluation is often necessary. For patients showing a phenotype consistent with androgen effects, the most useful initial tests should include measurements of total testosterone, dehydroepiandrosterone sulphate, and 17-hydroxyprogesterone [134]. If oestrogen effects are more pronounced instead, screening tests should include LH and oestradiol for girls, and LH, β-human chorionic gonadotrophin, and oestradiol for boys. FSH levels have more limited usefulness in differentiating children with GnRH-dependent precocious puberty from non-progressive variants [135]. All these measurements should be performed in the morning using high-sensitivity assays designed for paediatric patients.

In patients with clinical sexual precocity and basal prepubertal LH, the gold standard for differentiating precocious puberty is the assessment of gonadotrophins (mainly LH) following stimulation with GnRH agonists [135, 136], which helps in establishing the level of activation of the gonadotroph axis. While several protocols have been used thus far [137–139], but an LH peak higher than 5 IU/L is indicative of an activated gonadotroph axis [140]. Baseline random LH measured through ultra-sensitive assay has been suggested as useful to assess the activation of the gonadotrophic axis, avoiding the need for GnRH testing [141]. However, data are not consistent, with a wide range of diagnostic sensitivity (from 60 to 100%) and cut-off values (ranging from 0.1 to 1.5 IU/L) [140, 142, 143]. Basal and GnRH-stimulated FSH concentrations do not seem to be helpful [135, 141], although suppressed GnRH-stimulated FSH concentrations suggest peripheral precocious puberty.

In contrast to girls, where low oestradiol concentrations do not rule out the diagnosis of precocious puberty [144, 145], in boys testosterone is an excellent marker for sexual precocity, because prepubertal concentrations of this hormone effectively excludes the diagnosis of precocious puberty [135].

Pituitary magnetic resonance imaging (MRI)

MRI is the gold standard for the evaluation of the pituitary gland in the paediatric and transition-age population [146–148], providing morphological information and allowing the evaluation of size, signal characteristics, and vascularisation [148]. The adenohypophysis is isointense to grey matter on non-contrast T1 and T2-weighted standard Spin Echo sequences [149], whereas the neurohypophysis is characteristically hyperintense on T1 and hypointense on T2 sequences [149]. An appropriate imaging protocol should include sagittal and coronal T1-weighted and T2-weighted sequences, as well as contrast-enhanced T1- weighted images following intravenous injection of gadolinium [150]: normally, the pituitary gland enhances after gadolinium administration [148, 149]. Due to the small dimensions of the sellar structures and potential intrinsic lesions, acquiring small field-of-view images is essential [150], with either 2 or 3-mm sections obtained with 1.5 T scanning fields or 1.0 to 1.5-mm sections obtained with 3 T scanning[150].

Pituitary tumours have typically delayed enhancement and washout characteristics [148, 149]. Microadenomas are typically hypointense on both unenhanced and contrast-enhanced sequences, becoming iso/hyperintense to the normal pituitary gland in delayed sequences [148]. Conversely, macroadenomas are usually isointense in

Fig. 2 GH-secreting macroadenoma in 21-year-old patient. **A** and **B** illustrate coronal T1-weighted post-contrast and T2-weighted MRI images at diagnosis showing a large homogeneous pituitary mass with intra and suprasellar extension, compression, and upward stretching of the optic chiasm. In addition, there is a cavernous sinus extension, internal carotid artery compression. **C** shows sagittal T1-weighted MRI images with the presence of a large homogeneous pituitary mass with partial hyper attenuated margins

T1-weighted images and present intense contrast enhancement after gadolinium injection [148].

In adult patients with acromegaly, T2-hypointense adenomas are more common, smaller, and less invasive compared to T2-isointense and hyperintense tumours [151]. Moreover, patients with T2-hypointense adenomas also have higher IGF1 values at baseline [151, 152]. T2-weighted signal intensity is a marker for the granulation pattern [153, 154]; accordingly, T2-hypointense adenomas have been linked with better hormonal responses and greater tumour shrinkage after presurgical somatostatin analogue administration [151, 153, 155]. Currently, the few data reporting MRI findings in the paediatric and transition-age population mainly derive from retrospective studies. In the cohort of Rostmoyan et al., the median age of rapid growth onset was 13 years (interquartile range 9–15), pituitary macroadenomas were more prevalent than microadenomas (84.3 vs 15.7%), with 15% of macroadenomas classified as 'giant' adenomas (> 4 cm); extrasellar extension was found in 89% of macroadenomas and extrasellar invasion in 64%. No differences were found between males and females [39]. In another study, Colao et al. reported data on the diagnosis and treatment of patients with GH-secreting adenomas with clinical onset in adolescence. Thirteen patients were enrolled, with a mean age of 17 ± 2 years; on MRI evaluation, the mean maximal tumour diameter was 21.8 ± 5.4 mm, and the mean tumour volume was 2756 ± 1895 mm^3 [3, 41].

In conclusion, a pituitary MRI with an appropriate imaging protocol is mandatory for the evaluation of the pituitary gland in the paediatric and transition-age population with suspected gigantism (Fig. 2).

Conclusions

Human growth is a complex process and discriminating healthy tall children from those affected by acro-gigantism due to underlying diseases, either related to genetic (FIPA, and MEN1, more rarely CCS, MAS, 3PAs, MAX-associated tumours, NF1, and the recent PAM variants), or endocrine alterations (hyperthyroidism, obesity), is a compelling challenge. In general, females tend to receive a diagnosis of gigantism at a younger age than males, therefore males are more likely to be diagnosed during the transition age. A thorough clinical evaluation, using country- and disease-specific growth charts, is crucial before the biochemical assessment with GH and IGF1 measurements. Currently, a dedicated IGF1 reference range to guide the difficult differential diagnosis between constitutional tall stature and gigantism is still lacking. Nevertheless, the pathological effects of the prolonged exposition to supraphysiological levels of GH and IGF1 can cause systemic complications, mainly metabolic and cardiovascular; therefore, the clinical evaluation of pubertal staging and other signs and symptoms is of most importance, especially during the transition age.

Author contributions Dr Sbardella, Prof Grossmann, and Prof Isidori contributed to the study's conception and design. Material preparation,

Declarations

Conflict of interest The authors have no conflicts of interest relevant to this article to disclose.

Ethical approval No approval needed.

Research involving human participants and/or animals No patient/animal was involved in the present research.

Consent to participate Not applicable.

Consent for publication All Authors give consent for publication.

References

1. Meazza C et al (2017) Tall stature: a difficult diagnosis? Ital J Pediatr 43(1):66
2. Jee YH, Baron J (2016) The biology of stature. J Pediatr 173:32–38
3. Baron J et al (2015) Short and tall stature: a new paradigm emerges. Nat Rev Endocrinol 11(12):735–746
4. Camacho-Hubner C (2000) Normal Physiology of Growth Hormone and Insulin-Like Growth Factors in Childhood, in Endotext, K.R. Feingold, et al., Editors. South Dartmouth (MA)
5. Sbardella E et al (2017) Baseline morning cortisol level as a predictor of pituitary-adrenal reserve: a comparison across three assays. Clin Endocrinol 86(2):177–184
6. Corredor B et al (2019) Tall stature: a challenge for clinicians. Curr Pediatr Rev 15(1):10–21
7. Sbardella E et al (2020) GH deficiency in cancer survivors in the transition age: diagnosis and therapy. Pituitary 23(4):432–456
8. Leung AKC, Leung AAC, Hon KL (2019) Tall stature in children. Adv Pediatr 66:161–176
9. Albuquerque EVA, Scalco RC, Jorge AAL (2017) MANAGEMENT OF ENDOCRINE DISEASE: diagnostic and therapeutic approach of tall stature. Eur J Endocrinol 176(6):R339–R353
10. Bruinsma FJ et al (2006) Concern about tall stature during adolescence and depression in later life. J Affect Disord 91(2–3):145–152
11. Stalman SE et al (2015) Diagnostic work-up and follow-up in children with tall stature: a simplified algorithm for clinical practice. J Clin Res Pediatr Endocrinol 7(4):260–267
12. Zargham S, Crotty JE (2014) Tall stature. Pediatr Rev 35(12):538–539 (**discussion 539**)
13. Barstow C, Rerucha C (2015) Evaluation of short and tall stature in children. Am Fam Physician 92(1):43–50
14. Coutant R et al (2017) How to investigate a child with excessive growth? Ann Endocrinol 78(2):98–103
15. Iughetti L, Bergomi A, Bernasconi S (2003) Diagnostic approach and therapy of overgrowth and tall stature in childhood. Minerva Pediatr 55(6):563–582
16. Tatton-Brown K, Rahman N (2007) Sotos syndrome. Eur J Hum Genet 15(3):264–271
17. Manor J, Lalani SR (2020) Overgrowth syndromes-evaluation, diagnosis, and management. Front Pediatr 8:574857
18. Lauffer P et al (2019) Towards a rational and efficient diagnostic approach in children referred for tall stature and/or accelerated growth to the general paediatrician. Horm Res Paediatr 91(5):293–310
19. Narayanaswamy V, Rettig KR, Bhowmick SK (2008) Excessive growth. Clin Pediatr 47(7):705–708
20. Etxabe J et al (1993) Acromegaly: an epidemiological study. J Endocrinol Invest 16(3):181–187
21. Lodish MB, Trivellin G, Stratakis CA (2016) Pituitary gigantism: update on molecular biology and management. Curr Opin Endocrinol Diabetes Obes 23(1):72–80
22. George, M.M., E.A. Eugster, and S.D. Chernausek, *Pituitary Gigantism*, in *Endotext*, K.R. Feingold, et al., Editors. 2000: South Dartmouth (MA).
23. Natale V, Rajagopalan A (2014) Worldwide variation in human growth and the World Health Organization growth standards: a systematic review. BMJ Open 4(1):e003735
24. de Onis M et al (2007) Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 85(9):660–667
25. Herath M et al (2019) Paediatric and young adult manifestations and outcomes of multiple endocrine neoplasia type 1. Clin Endocrinol 91(5):633–638
26. Spaziani M et al (2021) Hypothalamo-pituitary axis and puberty. Mol Cell Endocrinol 520:111094
27. Marshall WA, Tanner JM (1970) Variations in the pattern of pubertal changes in boys. Arch Dis Child 45(239):13–23
28. Davies JH, Cheetham T (2014) Investigation and management of tall stature. Arch Dis Child 99(8):772–777
29. Upners EN et al (2021) Does height and IGF-I determine pubertal timing in girls? Pediatr Res 90(1):176–183
30. Carel JC et al (2004) Precocious puberty and statural growth. Hum Reprod Update 10(2):135–147
31. Chen M, Eugster EA (2015) Central precocious puberty: update on diagnosis and treatment. Paediatr Drugs 17(4):273–281
32. Sbardella E et al (2019) ENDOCRINOLOGY AND ADOLESCENCE: dealing with transition in young patients with pituitary disorders. Eur J Endocrinol 181(4):R155–R171
33. Liu G et al (2021) Obesity is a risk factor for central precocious puberty: a case-control study. BMC Pediatr 21(1):509
34. Zhai X et al (2021) Clinical characteristics and management of patients with mccune-albright syndrome with GH excess and

precocious puberty: a case series and literature review. Front Endocrinol 12:672394

35. Carmi D et al (1999) Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics 103(6 Pt 1):1257–1262

36. Aksglaede L et al (2013) 47, XXY Klinefelter syndrome: clinical characteristics and age-specific recommendations for medical management. Am J Med Genet C Semin Med Genet 163C(1):55–63

37. Cunha C et al (2021) Successful treatment of pituitary gigantism. BMJ Case Rep 14(12):e247989

38. Rollins BY, Francis LA (2021) Off the charts: identifying and visualizing body mass index trajectories of rural, poor youth. J Pediatr 228:147–1542

39. Rostomyan L et al (2015) Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer 22(5):745–757

40. Bondanelli M et al (2005) Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism. Metabolism 54(9):1174–1180

41. Colao A et al (2007) Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome. Clin Endocrinol 66(5):714–722

42. Feola T et al (2023) Sellar and parasellar lesions in the transition age: a retrospective Italian multi-centre study. J Endocrinol Invest 46(1):181–188

43. Tanner JM, Whitehouse RH, Takaishi M (1966) Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II Arch Dis Child 41(220):613–635

44. Prokop-Piotrkowska M et al (2021) Traditional and new methods of bone age assessment-an overview. J Clin Res Pediatr Endocrinol 13(3):251–262

45. Brook CG, Hindmarsh PC, Healy MJ (1986) A better way to detect growth failure. Br Med J Clin Res Ed 293(6556):1186

46. Pagani S et al (2017) Analysis of growth hormone receptor gene expression in tall and short stature children. J Pediatr Endocrinol Metab 30(4):427–430

47. Butenandt O, Bechtold S, Meidert A (2005) Final height in patients with constitutional delay of growth and development from tall statured families. J Pediatr Endocrinol Metab 18(2):165–169

48. Erkula G et al (2002) Growth and maturation in Marfan syndrome. Am J Med Genet 109(2):100–115

49. Kwun Y et al (2015) Disease-specific growth charts of Marfan syndrome patients in Korea. J Korean Med Sci 30(7):911–916

50. Benoist G et al (2018) Skeletal evolution in Marfan syndrome: growth curves from a French national cohort. Pediatr Res 83(1–1):71–77

51. Attias D et al (2009) Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. Circulation 120(25):2541–2549

52. Vergier J et al (2018) Investigation of tall stature in children: diagnostic work-up, review of the main causes. Arch Pediatr 25(2):163–169

53. Boguslawska A, Korbonits M (2021) Genetics of acromegaly and gigantism. J Clin Med 10(7):1377

54. Beckers A et al (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34(2):239–277

55. Daly AF et al (2010) Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and

pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95(11):E373–E383

56. Igreja S et al (2010) Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat 31(8):950–960

57. Cazabat L et al (2012) Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metab 97(4):E663–E670

58. Marques P et al (2020) Significant benefits of AIP testing and clinical screening in familial isolated and young-onset pituitary tumors. J Clin Endocrinol Metab. https://doi.org/10.1530/ey.17.1.10

59. Tichomirowa MA et al (2011) High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 165(4):509–515

60. Cuny T et al (2013) Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. Eur J Endocrinol 168(4):533–541

61. Hernandez-Ramirez LC et al (2015) Landscape of familial isolated and young-onset pituitary adenomas: prospective diagnosis in AIP mutation carriers. J Clin Endocrinol Metab 100(9):E1242–E1254

62. Trarbach EB et al (2021) Genetics, clinical features and outcomes of non-syndromic pituitary gigantism: experience of a single center from Sao Paulo. Brazil Pituitary 24(2):252–261

63. Dutta P et al (2019) Surgery, octreotide, temozolomide, bevacizumab, radiotherapy, and pegvisomant treatment of an AIP mutation positive child. J Clin Endocrinol Metab 104(8):3539–3544

64. Trivellin G et al (2023) Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion. medRxiv. https://doi.org/10.3389/fendo.2023.1166076

65. Thakker RV et al (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97(9):2990–3011

66. Lemos MC, Thakker RV (2008) Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 29(1):22–32

67. Concolino P, Costella A, Capoluongo E (2016) Multiple endocrine neoplasia type 1 (MEN1): an update of 208 new germline variants reported in the last nine years. Cancer Genet 209(1–2):36–41

68. Bartsch DK, Langer P, Rothmund M (2007) Surgical aspects of gastrinoma in multiple endocrine neoplasia type 1. Wien Klin Wochenschr 119(19–20):602–608

69. Agarwal SK (2013) Multiple endocrine neoplasia type 1. Front Horm Res 41:1–15

70. Kamilaris CDC, Stratakis CA (2019) Multiple endocrine neoplasia type 1 (MEN1): an update and the significance of early genetic and clinical diagnosis. Front Endocrinol 10:339

71. Falchetti A (2017) Genetics of multiple endocrine neoplasia type 1 syndrome: what's new and what's old. F100Res 6:73

72. Syro LV et al (2012) Pituitary tumors in patients with MEN1 syndrome. Clinics 67(Suppl 1):43–48

73. Daly AF et al (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege. Belgium J Clin Endocrinol Metab 91(12):4769–4775

74. de Laat JM et al (2015) Long-term natural course of pituitary tumors in patients with MEN1: results from the Dutch-MEN1 study group (DMSG). J Clin Endocrinol Metab 100(9):3288–3296

75. Goudet P et al (2015) MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'etude des tumeurs endocrines. J Clin Endocrinol Metab 100(4):1568–1577

76. Manoharan J et al (2017) Is routine screening of young asymptomatic MEN1 patients necessary? World J Surg 41(8):2026–2032

77. Shariq OA et al (2022) Multiple endocrine neoplasia type 1 in children and adolescents: clinical features and treatment outcomes. Surgery 171(1):77–87

78. Garby L et al (2012) Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases. J Clin Endocrinol Metab 97(6):2093–2104

79. Borson-Chazot F et al (2012) Acromegaly induced by ectopic secretion of GHRH: a review 30 years after GHRH discovery. Ann Endocrinol 73(6):497–502

80. Srirangam Nadhamuni V et al (2021) GHRH secretion from a pancreatic neuroendocrine tumor causing gigantism in a patient with MEN1. Endocrinol Diabetes Metab Case Rep. https://doi.org/10.1530/EDM-20-0208

81. Pellegata NS et al (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 103(42):15558–15563

82. Frederiksen A et al (2019) Clinical features of multiple endocrine neoplasia type 4: novel pathogenic variant and review of published cases. J Clin Endocrinol Metab 104(9):3637–3646

83. Agarwal SK, Mateo CM, Marx SJ (2009) Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 94(5):1826–1834

84. Occhi G et al (2013) A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet 9(3):e1003350

85. Sambugaro S et al (2015) Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region. Endocrine 49(1):58–64

86. Yamamoto M, Takahashi Y (2022) Genetic and epigenetic pathogenesis of acromegaly. Cancers 14(16):3861

87. Espiard S et al (2020) Frequency and incidence of carney complex manifestations: a prospective multicenter study with a three-year follow-up. J Clin Endocrinol Metab 105(3):e436

88. Forlino A et al (2014) PRKACB and Carney complex. N Engl J Med 370(11):1065–1067

89. Javaid MK et al (2019) Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. Orphanet J Rare Dis 14(1):139

90. Xekouki P et al (2019) The 3PAs: an update on the association of pheochromocytomas, paragangliomas, and pituitary tumors. Horm Metab Res 51(7):419–436

91. Daly AF et al (2018) Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions. Endocr Relat Cancer 25(5):L37–L42

92. Hannah-Shmouni F et al (2022) Neurofibromatosis type 1 Has a wide spectrum of growth hormone excess. J Clin Med 11(8):2168

93. Williamson S, Greene SA (2010) Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland. Clin Endocrinol 72(3):358–363

94. Havgaard Kjaer R, Smedegard Andersen M, Hansen D (2015) Increasing incidence of juvenile thyrotoxicosis in denmark: a nationwide study, 1998–2012. Horm Res Paediatr 84(2):102–107

95. Wong GW, Cheng PS (2001) Increasing incidence of childhood Graves' disease in Hong Kong: a follow-up study. Clin Endocrinol (Oxf) 54(4):547–550

96. Leger J, Carel JC (2018) Diagnosis and management of hyperthyroidism from prenatal life to adolescence. Best Pract Res Clin Endocrinol Metab 32(4):373–386

97. Wong GW, Lai J, Cheng PS (1999) Growth in childhood thyrotoxicosis. Eur J Pediatr 158(10):776–779

98. Buckler JM, Willgerodt H, Keller E (1986) Growth in thyrotoxicosis. Arch Dis Child 61(5):464–471

99. Samuels MH et al (1989) The effect of altered thyroid status on pituitary hormone messenger ribonucleic acid concentrations in the rat. Endocrinology 124(5):2277–2282

100. Chernausek SD et al (1983) Growth hormone secretion and plasma somatomedin-C in primary hypothyroidism. Clin Endocrinol 19(3):337–344

101. Cavaliere H, Knobel M, Medeiros-Neto G (1987) Effect of thyroid hormone therapy on plasma insulin-like growth factor I levels in normal subjects, hypothyroid patients and endemic cretins. Horm Res 25(3):132–139

102. Angervo M et al (1993) Thyroxine treatment increases circulating levels of insulin-like growth factor binding protein-1: a placebo-controlled study. Clin Endocrinol 38(5):547–551

103. Smith TJ (2021) Insulin-like growth factor pathway and the thyroid. Front Endocrinol 12:653627

104. Aksglaede L et al (2009) Age at puberty and the emerging obesity epidemic. PLoS ONE 4(12):e8450

105. Johnson W et al (2012) Patterns of linear growth and skeletal maturation from birth to 18 years of age in overweight young adults. Int J Obes 36(4):535–541

106. Stovitz SD et al (2011) Growing into obesity: patterns of height growth in those who become normal weight, overweight, or obese as young adults. Am J Hum Biol 23(5):635–641

107. Williams T et al (1984) Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction. N Engl J Med 311(22):1403–1407

108. Luque RM, Park S, Kineman RD (2008) Role of endogenous somatostatin in regulating GH output under basal conditions and in response to metabolic extremes. Mol Cell Endocrinol 286(1–2):155–168

109. Bouhours-Nouet N et al (2007) The insulin-like growth factor-I response to growth hormone is increased in prepubertal children with obesity and tall stature. J Clin Endocrinol Metab 92(2):629–635

110. Zhu JF et al (2010) Plasma ghrelin levels and polymorphisms of ghrelin gene in Chinese obese children and adolescents. Ir J Med Sci 179(3):345–349

111. Gomez JM, American Academy of Pediatrics Committee on Sports (2005) Use of performance-enhancing substances. Pediatrics 115(4):1103–1106

112. Brennan BP et al (2011) Human growth hormone abuse in male weightlifters. Am J Addict 20(1):9–13

113. Rickert VI et al (1992) Human growth hormone: a new substance of abuse among adolescents? Clin Pediatr 31(12):723–726

114. Rogol AD (2009) Growth hormone and the adolescent athlete: What are the data for its safety and efficacy as an ergogenic agent? Growth Horm IGF Res 19(4):294–299

115. Spaziani M et al (2021) Clinical, diagnostic, and therapeutic aspects of growth hormone deficiency during the transition period: review of the literature. Front Endocrinol 12:634288

116. Guha N et al (2010) Serum insulin-like growth factor-I and procollagen type III N-terminal peptide in adolescent elite athletes: implications for the detection of growth hormone abuse in sport. J Clin Endocrinol Metab 95(6):2969–2976

117. Dickerman Z, Loewinger J, Laron Z (1984) The pattern of growth in children with constitutional tall stature from birth to age 9 years. A longitudinal study. Acta Paediatr Scand 73(4):530–536

118. Latronico AC, Brito VN, Carel JC (2016) Causes, diagnosis, and treatment of central precocious puberty. Lancet Diabetes Endocrinol 4(3):265–274

119. Sbardella E et al (2021) A clinical approach to parasellar lesions in the transition age. J Neuroendocrinol 33(6):e12995

120. Barkan AL, Beitins IZ, Kelch RP (1988) Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 67(1):69–73

121. Juul A et al (1994) Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78(3):744–752

122. Holl RW et al (1999) Suppression of growth hormone by oral glucose in the evaluation of tall stature. Horm Res 51(1):20–24

123. Creo AL, Lteif AN (2016) Pituitary gigantism: a retrospective case series. J Pediatr Endocrinol Metab 29(5):597–602

124. Selenou C et al (2022) IGF2: development, genetic and epigenetic abnormalities. Cells 11(12):1886

125. Clemmons DR (2011) Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 57(4):555–559

126. Karavitaki N et al (2009) The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly. Clin Endocrinol 71(6):840–845

127. Sherlock M et al (2009) Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly. Clin Endocrinol 71(1):74–81

128. Eugster EA, Pescovitz OH (1999) Gigantism. J Clin Endocrinol Metab 84(12):4379–4384

129. Katznelson L et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951

130. Freda PU et al (2003) Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary 6(4):175–180

131. Bonfig W (2017) Growth and development in children with classic congenital adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes 24(1):39–42

132. Hamblin R et al (2022) Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance. Lancet Diabetes Endocrinol 10(8):581–588

133. Sbardella E et al (2020) Late effects of parasellar lesion treatment: hypogonadism and infertility. Neuroendocrinology 110(9–10):868–881

134. Tenuta M et al (2021) Somatotropic-testicular axis: a crosstalk between GH/IGF-I and gonadal hormones during development, transition, and adult age. Andrology 9(1):168–184

135. Brito VN et al (2008) Update on the etiology, diagnosis and therapeutic management of sexual precocity. Arq Bras Endocrinol Metabol 52(1):18–31

136. Partsch CJ, Heger S, Sippell WG (2002) Management and outcome of central precocious puberty. Clin Endocrinol 56(2):129–148

137. Freire AV et al (2013) High diagnostic accuracy of subcutaneous triptorelin test compared with GnRH test for diagnosing central precocious puberty in girls. Clin Endocrinol 78(3):398–404

138. Cavallo A et al (1995) A simplified gonadotrophin-releasing hormone test for precocious puberty. Clin Endocrinol 42(6):641–646

139. Lawson ML, Cohen N (1999) A single sample subcutaneous luteinizing hormone (LH)-releasing hormone (LHRH) stimulation test for monitoring LH suppression in children with central precocious puberty receiving LHRH agonists. J Clin Endocrinol Metab 84(12):4536–4540

140. Neely EK et al (1995) Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr 127(1):40–46

141. Brito VN et al (1999) Diagnostic value of fluorometric assays in the evaluation of precocious puberty. J Clin Endocrinol Metab 84(10):3539–3544

142. Houk CP, Kunselman AR, Lee PA (2009) Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls. Pediatrics 123(6):e1059–e1063

143. Pasternak Y et al (2012) The utility of basal serum LH in prediction of central precocious puberty in girls. Eur J Endocrinol 166(2):295–299

144. Carel JC, Leger J (2008) Clinical practice. Precocious puberty N Engl J Med 358(22):2366–2377

145. Carel JC et al (2009) Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 123(4):e752–e762

146. Adamsbaum C, Chaussain JL (1996) Diagnostic strategies in pediatric imaging. Horm Res 46(4–5):165–169

147. Doraiswamy PM et al (1992) MR assessment of pituitary gland morphology in healthy volunteers: age- and gender-related differences. AJNR Am J Neuroradiol 13(5):1295–1299

148. Argyropoulou MI, Kiortsis DN (2005) MRI of the hypothalamic-pituitary axis in children. Pediatr Radiol 35(11):1045–1055

149. Bashari WA et al (2019) Modern imaging of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 33(2):101278

150. Bou-Ayache JM, Delman BN (2016) Advances in imaging of the pediatric pituitary gland. Endocrinol Metab Clin North Am 45(2):443–452

151. Potorac I, Beckers A, Bonneville JF (2017) T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses

to somatostatin receptor ligands in acromegaly: a perspective. Pituitary 20(1):116–120

152. Chiloiro S et al (2022) Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly. Endocrine 78(2):343–353

153. Heck A et al (2016) Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52(2):333–343

154. De Alcubierre D et al (2023) Pituitary adenoma consistency affects postoperative hormone function: a retrospective study. BMC Endocr Disord 23(1):92

155. Feola T et al (2019) Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab 104(7):2892–2902

Authors and Affiliations

V. Sada[1] · G. Puliani[2] · T. Feola[1,3] · R. Pirchio[4] · R. Pofi[1,5] · F. Sesti[1] · D. De Alcubierre[1] · M. E. Amodeo[6] · F. D'Aniello[6] · L. Vincenzi[1] · D. Gianfrilli[1] · A. M. Isidori[1,7] · A. B. Grossman[8,9] · E. Sbardella[1] on behalf of the TALENT group

✉ E. Sbardella
emi.sbardella@uniroma1.it

V. Sada
valentina.sada@uniroma1.it

G. Puliani
giulia.puliani@ifo.it

T. Feola
tiziana.feola@uniroma1.it

R. Pirchio
pirchio.rosa@libero.it

R. Pofi
riccardo.pofi@ocdem.ox.ac.uk

F. Sesti
franz.sesti@uniroma1.it

D. De Alcubierre
dario.dealcubierre@uniroma1.it

M. E. Amodeo
mariaelisaamodeo@gmail.com

F. D'Aniello
francesco.daniello@opbg.net

L. Vincenzi
ludovica.vincenzi@uniroma1.it

D. Gianfrilli
daniele.gianfrilli@uniroma1.it

A. M. Isidori
andrea.isidori@uniroma1.it

A. B. Grossman
ashley.grossman@ocdem.ox.ac.uk

1 Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy

2 Oncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy

3 Neuroendocrinology, Neuromed Institute, IRCCS, Pozzilli, Italy

4 Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Degli Studi di Napoli "Federico II", Naples, Italy

5 Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Oxford University Hospitals, NHS Trust, Oxford, UK

6 Dipartimento Pediatrico Universitario Ospedaliero, Bambino Gesù Children Hospital, Rome, Italy

7 Centre for Rare Diseases (ENDO-ERN Accredited), Policlinico Umberto I, Rome, Italy

8 Green Templeton College, University of Oxford, Oxford, UK

9 Centre for Endocrinology, Barts and the London School of Medicine, London, UK